JP2022552786A5 - - Google Patents

Info

Publication number
JP2022552786A5
JP2022552786A5 JP2022519779A JP2022519779A JP2022552786A5 JP 2022552786 A5 JP2022552786 A5 JP 2022552786A5 JP 2022519779 A JP2022519779 A JP 2022519779A JP 2022519779 A JP2022519779 A JP 2022519779A JP 2022552786 A5 JP2022552786 A5 JP 2022552786A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
nos
epha3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519779A
Other languages
English (en)
Japanese (ja)
Other versions
JP7846002B2 (ja
JP2022552786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/051090 external-priority patent/WO2021068040A1/en
Publication of JP2022552786A publication Critical patent/JP2022552786A/ja
Publication of JP2022552786A5 publication Critical patent/JP2022552786A5/ja
Priority to JP2025175565A priority Critical patent/JP2026031931A/ja
Application granted granted Critical
Publication of JP7846002B2 publication Critical patent/JP7846002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519779A 2019-10-09 2020-10-09 標的化ｅｐｈａ３及びその使用 Active JP7846002B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025175565A JP2026031931A (ja) 2019-10-09 2025-10-17 標的化ｅｐｈａ３及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019903802A AU2019903802A0 (en) 2019-10-09 Targeting EphA3 and uses thereof
AU2019903802 2019-10-09
PCT/AU2020/051090 WO2021068040A1 (en) 2019-10-09 2020-10-09 Targeting epha3 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025175565A Division JP2026031931A (ja) 2019-10-09 2025-10-17 標的化ｅｐｈａ３及びその使用

Publications (3)

Publication Number Publication Date
JP2022552786A JP2022552786A (ja) 2022-12-20
JP2022552786A5 true JP2022552786A5 (enExample) 2023-10-18
JP7846002B2 JP7846002B2 (ja) 2026-04-14

Family

ID=75436706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519779A Active JP7846002B2 (ja) 2019-10-09 2020-10-09 標的化ｅｐｈａ３及びその使用
JP2025175565A Pending JP2026031931A (ja) 2019-10-09 2025-10-17 標的化ｅｐｈａ３及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025175565A Pending JP2026031931A (ja) 2019-10-09 2025-10-17 標的化ｅｐｈａ３及びその使用

Country Status (9)

Country Link
US (1) US20260055195A1 (enExample)
EP (1) EP4041771A4 (enExample)
JP (2) JP7846002B2 (enExample)
KR (1) KR20220079574A (enExample)
CN (1) CN114787190A (enExample)
AU (1) AU2020363461A1 (enExample)
CA (1) CA3152930A1 (enExample)
IL (1) IL291937A (enExample)
WO (1) WO2021068040A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025241005A1 (en) * 2024-05-22 2025-11-27 The Council Of The Queensland Institute Of Medical Research Enhanced chimeric antigen receptor t cell composition and method of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679986C (en) * 2007-03-08 2018-03-06 Martin Lackmann Epha3 antibodies for the treatment of solid tumors
WO2010102244A1 (en) * 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
PT2488554T (pt) * 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
EP2582388A4 (en) * 2010-06-18 2014-04-16 Kalobios Pharmaceuticals Inc IDENTIFYING EPHA3 AS A MARKER FOR THE PRESENCE OF A SOLID TUMOR
US9975942B2 (en) * 2013-11-11 2018-05-22 Wake Forest University Health Services EPHA3 And multi-valent targeting of tumors
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
EP3341413A4 (en) * 2015-08-24 2019-07-17 Trustees of Boston University THERAPY AND IMAGING FOR CANCER AND STROKE ON MONOCLONAL ANTI-DESPR ANTIBODIES
JP2019520332A (ja) * 2016-05-23 2019-07-18 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｃｍｖエピトープ
EP3512883A1 (en) * 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
WO2018053649A2 (en) * 2016-09-23 2018-03-29 Mcmaster University Epha2 and epha3-binding agents and uses thereof
WO2019099707A1 (en) * 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
AR120430A1 (es) * 2019-11-08 2022-02-16 Humanigen Inc Células car-t dirigidas a epha3 para el tratamiento de tumores

Similar Documents

Publication Publication Date Title
EP3515951B1 (en) Binding molecules that modulate a biological activity expressed by a cell
CN111018986B (zh) 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
CN114380908B (zh) 抗ox40抗体及其应用
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
KR101944557B1 (ko) 에이치엘에이 제한된, 펩타이드­특이성 항원 결합 단백질
US11365260B2 (en) Agonistic 4-1BB monoclonal antibody
JP2019513370A5 (enExample)
JP2019525771A5 (enExample)
JP2022542559A5 (enExample)
CN111393529A (zh) 与ox40l非竞争结合的抗ox40抗体
KR20230040333A (ko) 다중특이성 키메라 항원 수용체 및 이의 용도
JP2024509557A (ja) ＮＫｐ４６に対する抗体とその応用
CA3208935A1 (en) Bispecific chimeric antigen receptors binding to cd19 and cd22
TW202246340A (zh) 抗ctla-4抗體及其應用
JP2024516713A5 (enExample)
WO2025021027A1 (zh) 靶向人源cd7的抗体或其抗原结合片段及其应用
EP4480966A1 (en) Humanized anti-cd28 antibody and bispecific antibody thereof with anti-cd40 antibody
JP2024541476A5 (enExample)
US20250230249A1 (en) Humanized anti-gdnf family alpha-receptor 4 (grf-alpha-4) antibodies and chimeric antigen receptors
JP2023545517A5 (enExample)
WO2024193669A1 (zh) 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
CN116261596A (zh) T细胞和抗原呈递细胞接合器及其用途
AU2021317073A1 (en) Anti-CD22 single domain antibodies and therapeutic constructs